United States securities and exchange commission logo





                             January 9, 2024

       Brian S. John
       Chief Executive Officer
       Safety Shot, Inc.
       1061 E. Indiantown Rd., Ste. 110
       Jupiter, FL 33477

                                                        Re: Safety Shot, Inc.
                                                            Post-Effective
Amendment No. 3 on Form S-1
                                                            Filed December 27,
2023
                                                            File No. 333-258005

       Dear Brian S. John:

              We have conducted a limited review of the post-effective
amendment to your registration
       statement and have the following comments.

              Please respond to this letter by filing a post-effective
amendment and providing the
       requested information. If you do not believe a comment applies to your
facts and circumstances
       or do not believe an amendment is appropriate, please tell us why in
your response.

                After reviewing any amendment and the information you provide
in response to this
       letter, we may have additional comments.

       Post-Effective Amendment No. 3 to Form S-1

       Prospectus Summary, page 3

   1.                                                   We note your disclosure
on page 3 that you "launched Safety Shot in December 2023."
                                                        We also note your
disclosure on page 4 that "Safety Shot plans to launch initially online
                                                        and through Amazon in
the near future and plans to launch in Big Box stores in 2024."
                                                        Please revise your
disclosure to clarify this discrepancy and to discuss the current
                                                        production status and
commercialization of Safety Shot.
 Brian S. John
FirstName
Safety Shot,LastNameBrian S. John
             Inc.
Comapany
January     NameSafety Shot, Inc.
        9, 2024
January
Page 2 9, 2024 Page 2
FirstName LastName
2.       We note your disclosure that you have signed agreements to license
JW-700 to Taisho
         and JW-700 and Photocil products to Cosmofix Technovation Pvt Ltd and
Sanpellegrino
         Cosmetics. As these appear to be material to your business, please
revise to disclose
         the material terms of these agreements. Refer to Item 101(h)(4) of
Regulation S-K. To the
         extent your company is substantially dependent on these contracts,
please file them as
         exhibits to the registration statement, or tell us why you believe you
are not required to do
         so. Refer to Item 601(b)(10)(ii)(B) of Regulation S-K. To the extent
these contracts are
         not material, please refrain from highlighting them in the summary.
3.       We note your disclosure on page 3 regarding positioning the "Company
as a leader in
         the dynamic and growing market for nutritional supplements" and on
page 4 regarding
         your standing in the market and that your brand is synonymous with
standards of
         excellence. We also note your disclosure on page 6 that "Safety Shot
stands as a unique
         product in its category, unrivaled by any other company." Please
revise your disclosure to
         clarify the markets to which you refer and the standards by which you
assess your relative
         position. To the extent that some of these statements are intended to
be qualified to your
         belief, please revise your disclosure to state this and the basis, to
the extent material, for
         your belief.
Management's Discussion And Analysis Of Financial Condition And Results Of
Operations
Results of Operations, page 39

4.       We note your revised disclosure in response to comment 1. We note the
auditor's opinion
         raising substantial doubt about your ability to continue as a going
concern. Please revise
         this discussion to provide more specific information required by Item
303(b)(1) of
         Regulation S-K, including your ability and plans to generate cash and
whether you will
         have sufficient funds to meet your obligations, both in the short and
long term. For
         example, please clarify how long you believe your current cash would
fund your
         operations.
5.       We note the revised financial statements in response to prior comments
4 and 5. Please
         revise your discussion of period-to-period changes in your results of
operations to explain
         and quantify the factors that contributed to changes in your results
of operations. For
         example, you note on page 39 that you "generated $11,877 in revenues
for the three
         months ended September 30, 2023 compared to $85,467 revenues in the
three months
         ended September 30, 2022" but do not explain why your revenues
decreased from 2022 to
         2023. Refer to Item 303 of Regulation S-K.
Executive And Director Compensation, page 54

6.       Please revise your executive and director compensation disclosures to
include the
         information required by Item 402 of Regulation S-K for fiscal 2023.
 Brian S. John
FirstName
Safety Shot,LastNameBrian S. John
             Inc.
Comapany
January     NameSafety Shot, Inc.
        9, 2024
January
Page 3 9, 2024 Page 3
FirstName LastName
Where You Can Find Additional Information, page 70

7.       We note that you are incorporating by reference various reports and
registration
         statements previously filed with the Commission. We also note that you
have not filed an
         annual report on Form 10-K for your most recently completed fiscal
year. Please advise
         on your eligibility to incorporate by reference on Form S-1 given
general instruction VII.
         C. to Form S-1, which states that a registrant must have filed an
annual report required
         under Section 13(a) or Section 15(d) of the Exchange Act for its most
recently completed
         fiscal year in order to use incorporation by reference on Form S-1.
Exhibits

8.       We note that you have incorporated by reference a current report on
Form 8-K dated July
         10, 2023, which includes the Form of Asset Purchase Agreement entered
into between
         Jupiter Wellness, Inc. and GBB Labs, Inc. Please file the executed
version of this asset
         purchase agreement.
General

9.       We note the revised financial statements and related disclosure in
response to comment
         4. The risk factor on page 22 continues to warn, "[t]he historical
financial information
         included or incorporated by reference in the registration statements
of which this
         prospectus forms a part refers to the business as operated by us
before the Spin-off." As
         the financial statements have been updated to reflect your
discontinued operations, please
         further clarify the risk you are describing in this risk factor.
10.      We note your revised disclosure and response to prior comment 6
regarding the
         development and history of your business and reissue the comment in
part. We note from
         page 9 that you have eight full-time employees. Please revise to
clarify their roles and
         clarify statements such as on pages 3 and 30 that "[o]ur team includes
scientists,
         researchers, product developers, and business experts who collaborate
to create new
         products and enhance existing ones."
11.      We note your revised disclosure and response to prior comment 7 and
reissue the
         comment. Please further revise your disclosure to discuss the current
status
         of development and commercialization of your products, including but
not limited to:
         Safety Shot, Photocil, JW-700, JW-500, and NoStingz. In this regard,
please note:
             Safety and efficacy are determinations that are solely within the
authority of FDA or
             similar foreign regulators. Please revise to remove any statements
of safety and
             efficacy for any products that have not been approved by the FDA
or similar foreign
             regulators.
             Also, please remove references to the informal study and
prospective study from the
             summary. In the business section, you may present clinical trial
end points and
             objective data resulting from trials or studies without concluding
efficacy and you
             may state that your product candidates have been well tolerated,
if accurate. For the
 Brian S. John
Safety Shot, Inc.
January 9, 2024
Page 4
              informal study, further clarify whether you believe the results
are reliable and explain
              on what basis you made the determination.
12.    We note your revised disclosure and response to prior comment 8 and
reissue the
       comment. Please continue to revise the summary and related disclosure to
clarify the
       applicable regulatory schemes for your products and/or the applicable
exemption from
       FDA regulation, including but not limited to: Safety Shot, Photocil,
JW-700, JW-500, and
       NoStingz. In doing so, please address the following:
           We note your disclosure that "Safety Shot comprises 28 active
ingredients, all falling
           under the Generally Regarded As Safe (GRAS) category." Please revise
your
           disclosure in the summary, and more completely in the section
addressing
           government regulation, to clarify what the GRAS category is, and
that it is designated
           under the FDA.
           On page 4 of the registration statement, you state that you have
plans to file an IND
           application with the FDA for a modified version of Safety Shot, and
that you
           also plan to file for a pre-IND meeting to seek Orphan Drug
Designation for JW-500.
           Please disclose the timing of your current plans for these
submissions.
           Please revise the section addressing government regulations to
provide materially
           complete disclosure of the regulations relating to your products and
potential
           products, including FDA regulations. In doing so, describe the
Orphan Drug
           Designation and expedited 505(b)(2) pathway and clarify the basis
for your belief
           that JW-500 would qualify for this designation or accelerated
pathway.
           On page 46 you state that Safety Shot is a    nutritional
supplement, exempt from the
           approval or filing requirements mandated for pharmaceutical drugs by
the FDA or
           other regulatory agencies.    Clarify here and in the summary if
Safety shot is
           categorized as a food, a food additive, or a dietary supplement. To
the extent you
           state that "[f]rom a product and sales perspective, there are no
impediments or
           concerns raised by any governmental agency," revise to clarify this
statement,
           including whether the product was submitted to any governmental
agency for
           scrutiny.
           For the prospective study currently disclosed on page 5, clarify the
significance, if
           any, of approval of the study by the Institutional Review Board.
           We note your disclosure that you are subject to California
Proposition 65 and that
           there has been increasing regulatory activity globally regarding
PFAS. Please
FirstName LastNameBrian
           disclose whetherS.youJohn
                                   are currently required to provide any
warnings in connection
Comapany with
           NameSafety     Shot, Inc.
                 your products   pursuant to California Proposition 65 and
whether any of your
           products
January 9, 2024  Pagecontain
                       4      PFAS.
FirstName LastName
 Brian S. John
FirstName
Safety Shot,LastNameBrian S. John
             Inc.
Comapany
January     NameSafety Shot, Inc.
        9, 2024
January
Page 5 9, 2024 Page 5
FirstName LastName
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date.

       Please contact Juan Grana at 202-551-6034 or Abby Adams at 202-551-6902
with any
other questions.



                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Industrial
Applications and
                                                           Services
cc:      Arthur S. Marcus, Esq.